\-\ Texto\\:\\ \ \(0\)\
\-\ thin\\ appearing\ \(0\)\
\-\ aaox3\ \(0\)\
\-\ mmm\ \(3\)\
\-\ rrr\ \(3\)\
\-\ cta\\ b\\/l\ \(0\)\
\-\ abd\\ soft\\/nt\\/nd\\/nabs\ \(0\)\
\-\ ext\\ w\\/o\\ edema\ \(0\)\
\-\ referred\\ to\\ oncology\\ service\\ for\\ chemotherapy\\.\\ poor\\ prognosis\\.\ \(0\)\
\-\ \\â\\€\\¢\\ abd\\ ct\\:\\ too\\ numerous\\ to\\ count\\ low\\ attenuation\\ lesions\\ in\\ the\\ liver\\.\\ variable\\ in\\ size\\,\\ from\\ sub\\-centimeter\\ to\\ \\>4cm\\ coalescent\\ lesions\\.\\ \ \(0\)\
\-\ there\\ is\\ a\\ single\\ hypodense\\ lesion\\ in\\ the\\ spleen\\.\ \(0\)\
\-\ metastasis\\,\\ melanoma\ \(0\)\
\-\ \\â\\€\\¢\\ metastases\ \(0\)\
\-\ \\â\\€\\¢\\ abscesses\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ hepatocellular\\ carcinoma\ \(0\)\
\-\ 55\\ y\\.o\\.\\ man\\ with\\ weight\\ loss\\ and\\ fatigue\\ for\\ 1\\ month\ \(1\)\
\-\ metastatic\\ cancer\\ is\\ the\\ most\\ common\\ malignant\\ tumor\\ of\\ the\\ liver\\.\\ the\\ ratio\\ of\\ metastatic\\ disease\\ to\\ primary\\ liver\\ tumors\\ is\\ 18\\:1\\.\\ \\ imaging\\ appearance\\ varies\\ based\\ on\\ the\\ primary\\ tumor\\ origin\\.\\ lung\\,\\ gi\\,\\ lymphoma\\,\\ and\\ most\\ breast\\ cancers\\ are\\ hypovascular\\ lesions\\.\\ on\\ ct\\ these\\ lesions\\ will\\ generally\\ appear\\ as\\ low\\ attenuation\\ with\\ peripheral\\ enhancement\\.\\ \\ these\\ findings\\ indicate\\ a\\ necrotic\\/hypovascular\\ center\\ with\\ a\\ well\\ vascularized\\ viable\\ tumor\\ in\\ the\\ periphery\\.\\ endocrine\\,\\ renal\\,\\ thyroid\\,\\ sarcomas\\ and\\ melanomas\\ are\\ generally\\ hypervascular\\ lesions\\.\\ on\\ contrast\\ enhanced\\ ct\\ they\\ appear\\ hyperdense\\ in\\ late\\ arterial\\ phase\\ images\\.\\ some\\ lesions\\ can\\ have\\ variable\\ enhancement\\ secondary\\ to\\ internal\\ necrosis\\.\\ on\\ non\\-contrast\\ enhanced\\ ct\\ or\\ portal\\ venous\\ images\\ these\\ lesions\\ appear\\ iso\\-\\ or\\ hypodense\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ blake\\ sp\\ et\\ al\\:\\ liver\\ metastases\\ from\\ melanoma\\:\\ detection\\ with\\ multiphasic\\ contrast\\-enhanced\\ ct\\.\\ radiology\\.\\ 213\\(1\\)\\:92\\-6\\,\\ 1999\ \(0\)\
\-\ \\	\ \(2191\)\
\-\ paulson\\ ek\\ et\\ al\\:\\ carcinoid\\ metastases\\ to\\ the\\ liver\\:\\ role\\ of\\ triple\\-phase\\ helical\\ ct\\.\\ radiology\\.\\ 206\\(1\\)\\:143\\-50\\,\\ 1998\ \(0\)\
\-\ https\\:\\/\\/my\\.statdx\\.com\\/statdxmain\\.jsp\\#5\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lesions\\:\\ 0\\.059088278761651784\ \(0\)\
\-\ liver\\:\\ 0\\.05435833045816833\ \(0\)\
\-\ metastases\\:\\ 0\\.040414012362099454\ \(0\)\
\-\ appear\\:\\ 0\\.03871658778733153\ \(0\)\
\-\ variable\\:\\ 0\\.03360028447915264\ \(0\)\
\-\ hypodense\\:\\ 0\\.03360028447915264\ \(0\)\
\-\ \\-thin\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ \\-mmm\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ soft\\/nt\\/nd\\/nabs\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ \\-ext\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ 18\\:1\\.\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ necrotic\\/hypovascular\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ multiphasic\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ \\:92\\-6\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ paulson\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ triple\\-phase\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ \\:143\\-50\\:\\ 0\\.03252958828031918\ \(0\)\
\-\ melanoma\\:\\ 0\\.03218576478016967\ \(0\)\
\-\ \\-aaox3\\:\\ 0\\.029971849606666247\ \(0\)\
\-\ \\-rrr\\:\\ 0\\.029971849606666247\ \(0\)\
\-\ \\-cta\\:\\ 0\\.029971849606666247\ \(0\)\
\-\ \\-abd\\:\\ 0\\.029971849606666247\ \(0\)\
\-\ melanomas\\:\\ 0\\.029971849606666247\ \(0\)\
\-\ \\/\\/my\\.statdx\\.com\\/statdxmain\\.jsp\\:\\ 0\\.029971849606666247\ \(0\)\
\-\ \\:\\:\\ 0\\.029195290449943376\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.02891170390398317\ \(0\)\
\-\ 213\\:\\ 0\\.028475668395935013\ \(0\)\
\-\ ek\\:\\ 0\\.028475668395935013\ \(0\)\
\-\ 206\\:\\ 0\\.028475668395935013\ \(0\)\
\-\ generally\\:\\ 0\\.02838158763387821\ \(0\)\
\-\ enhanced\\:\\ 0\\.026984967710346634\ \(0\)\
\-\ al\\:\\ 0\\.026734771757020576\ \(0\)\
\-\ radiology\\:\\ 0\\.02665322315047751\ \(0\)\
\-\ coalescent\\:\\ 0\\.026590702994584492\ \(0\)\
\-\ vascularized\\:\\ 0\\.026590702994584492\ \(0\)\
\-\ blake\\:\\ 0\\.026590702994584492\ \(0\)\
\-\ ct\\:\\ 0\\.026464287528975117\ \(0\)\
\-\ sp\\:\\ 0\\.025917929722282077\ \(0\)\
\-\ et\\:\\ 0\\.025811058524887687\ \(0\)\
\-\ attenuation\\:\\ 0\\.025355137051114675\ \(0\)\
\-\ sub\\-centimeter\\:\\ 0\\.025349108025502526\ \(0\)\
\-\ hypovascular\\:\\ 0\\.025349108025502526\ \(0\)\
\-\ these\\:\\ 0\\.02461820692204251\ \(0\)\
\-\ iso\\-\\:\\ 0\\.023681266240472794\ \(0\)\
\-\ sarcomas\\:\\ 0\\.023064830503708344\ \(0\)\
\-\ helical\\:\\ 0\\.023064830503708344\ \(0\)\
\-\ 1\\:\\ 0\\.022509147984793802\ \(0\)\
\-\ viable\\:\\ 0\\.02207492649413388\ \(0\)\
\-\ tumor\\:\\ 0\\.02205423212115289\ \(0\)\
\-\ b\\/l\\:\\ 0\\.021475225647278624\ \(0\)\
\-\ varies\\:\\ 0\\.020651817708849805\ \(0\)\
\-\ 4cm\\:\\ 0\\.020367828627166674\ \(0\)\
\-\ oncology\\:\\ 0\\.02010414241321042\ \(0\)\
\-\ 1998\\:\\ 0\\.02010414241321042\ \(0\)\
\-\ https\\:\\ 0\\.019627346356088624\ \(0\)\
\-\ endocrine\\:\\ 0\\.019517187820480945\ \(0\)\
\-\ cancers\\:\\ 0\\.019010910619324178\ \(0\)\
\-\ carcinoid\\:\\ 0\\.01873744946746542\ \(0\)\
\-\ primary\\:\\ 0\\.01868180267819702\ \(0\)\
\-\ hypervascular\\:\\ 0\\.018650621063737768\ \(0\)\
\-\ role\\:\\ 0\\.018650621063737768\ \(0\)\
\-\ detection\\:\\ 0\\.018322401558141844\ \(0\)\
\-\ service\\:\\ 0\\.018244713701323276\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.018168627770685872\ \(0\)\
\-\ lymphoma\\:\\ 0\\.018023606157855983\ \(0\)\
\-\ indicate\\:\\ 0\\.01787906461407519\ \(0\)\
\-\ 1999\\:\\ 0\\.01787906461407519\ \(0\)\
\-\ w\\/o\\:\\ 0\\.01781008995351374\ \(0\)\
\-\ abscesses\\:\\ 0\\.01781008995351374\ \(0\)\
\-\ too\\:\\ 0\\.01767589200454372\ \(0\)\
\-\ contrast\\-enhanced\\:\\ 0\\.01767589200454372\ \(0\)\
\-\ periphery\\:\\ 0\\.017610579911926008\ \(0\)\
\-\ low\\:\\ 0\\.01753629559310996\ \(0\)\
\-\ ratio\\:\\ 0\\.01748332464967077\ \(0\)\
\-\ spleen\\:\\ 0\\.016959449146828013\ \(0\)\
\-\ enhancement\\:\\ 0\\.016903976133749343\ \(0\)\
\-\ fatigue\\:\\ 0\\.016852484066114903\ \(0\)\
\-\ abd\\:\\ 0\\.016697634622945046\ \(0\)\
\-\ portal\\:\\ 0\\.01659789782446564\ \(0\)\
\-\ late\\:\\ 0\\.016406164470477772\ \(0\)\
\-\ metastatic\\:\\ 0\\.015875346152148268\ \(0\)\
\-\ hyperdense\\:\\ 0\\.015764662884488908\ \(0\)\
\-\ center\\:\\ 0\\.015463267936096778\ \(0\)\
\-\ non\\-contrast\\:\\ 0\\.015391614482749541\ \(0\)\
\-\ 55\\:\\ 0\\.015286677452046463\ \(0\)\
\-\ prognosis\\:\\ 0\\.014956990734940006\ \(0\)\
\-\ phase\\:\\ 0\\.014832944200626409\ \(0\)\
\-\ most\\:\\ 0\\.014559668942642627\ \(0\)\
\-\ origin\\:\\ 0\\.014456378686404378\ \(0\)\
\-\ poor\\:\\ 0\\.014190793816939105\ \(0\)\
\-\ gi\\:\\ 0\\.014165257127475732\ \(0\)\
\-\ numerous\\:\\ 0\\.01413989594929211\ \(0\)\
\-\ appearing\\:\\ 0\\.014015640542994735\ \(0\)\
\-\ arterial\\:\\ 0\\.01380200962631982\ \(0\)\
\-\ count\\:\\ 0\\.013710892974694832\ \(0\)\
\-\ references\\:\\ 0\\.01311006728805023\ \(0\)\
\-\ thyroid\\:\\ 0\\.012923662158393766\ \(0\)\
\-\ single\\:\\ 0\\.012781034282252515\ \(0\)\
\-\ necrosis\\:\\ 0\\.012446866101271973\ \(0\)\
\-\ \\#\\:\\ 0\\.012367847302364902\ \(0\)\
\-\ images\\:\\ 0\\.012097888501471248\ \(0\)\
\-\ based\\:\\ 0\\.01202468768364192\ \(0\)\
\-\ referred\\:\\ 0\\.011898640012751444\ \(0\)\
\-\ tumors\\:\\ 0\\.011843971799522143\ \(0\)\
\-\ metastasis\\:\\ 0\\.01180349566900342\ \(0\)\
\-\ breast\\:\\ 0\\.011633055143286171\ \(0\)\
\-\ venous\\:\\ 0\\.011445703389140697\ \(0\)\
\-\ peripheral\\:\\ 0\\.01140934805171261\ \(0\)\
\-\ malignant\\:\\ 0\\.011397308768927309\ \(0\)\
\-\ they\\:\\ 0\\.01136142482098637\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.011302382970999503\ \(0\)\
\-\ weight\\:\\ 0\\.011302382970999503\ \(0\)\
\-\ on\\:\\ 0\\.010684738189895618\ \(0\)\
\-\ size\\:\\ 0\\.01057149768036447\ \(0\)\
\-\ internal\\:\\ 0\\.01057149768036447\ \(0\)\
\-\ \\>\\:\\ 0\\.010476632895455957\ \(0\)\
\-\ cancer\\:\\ 0\\.010365923484740832\ \(0\)\
\-\ \\,\\:\\ 0\\.009989301310601011\ \(0\)\
\-\ will\\:\\ 0\\.009865243610255136\ \(0\)\
\-\ some\\:\\ 0\\.009575381010578447\ \(0\)\
\-\ renal\\:\\ 0\\.009474079518295458\ \(0\)\
\-\ month\\:\\ 0\\.009459832253876787\ \(0\)\
\-\ to\\:\\ 0\\.009455382474752463\ \(0\)\
\-\ from\\:\\ 0\\.009346389026968356\ \(0\)\
\-\ 5\\:\\ 0\\.009225684215661119\ \(0\)\
\-\ loss\\:\\ 0\\.009153004326451806\ \(0\)\
\-\ lung\\:\\ 0\\.009133428487965852\ \(0\)\
\-\ y\\.o\\:\\ 0\\.009101031116556088\ \(0\)\
\-\ appearance\\:\\ 0\\.009018105449205319\ \(0\)\
\-\ carcinoma\\:\\ 0\\.00893700247238327\ \(0\)\
\-\ edema\\:\\ 0\\.008918536861370077\ \(0\)\
\-\ secondary\\:\\ 0\\.008815608732504825\ \(0\)\
\-\ are\\:\\ 0\\.008596855147819939\ \(0\)\
\-\ common\\:\\ 0\\.008251908531204418\ \(0\)\
\-\ in\\:\\ 0\\.00777485664465415\ \(0\)\
\-\ man\\:\\ 0\\.007457313074132838\ \(0\)\
\-\ or\\:\\ 0\\.007391311800470166\ \(0\)\
\-\ imaging\\:\\ 0\\.007387726289504069\ \(0\)\
\-\ can\\:\\ 0\\.007152112001730884\ \(0\)\
\-\ well\\:\\ 0\\.0071331400478548005\ \(0\)\
\-\ contrast\\:\\ 0\\.007058212866449835\ \(0\)\
\-\ have\\:\\ 0\\.006828184791015098\ \(0\)\
\-\ findings\\:\\ 0\\.006711575408819039\ \(0\)\
\-\ lesion\\:\\ 0\\.0064227130110717885\ \(0\)\
\-\ is\\:\\ 0\\.006224621162930542\ \(0\)\
\-\ for\\:\\ 0\\.005380871945702695\ \(0\)\
\-\ \\(\\:\\ 0\\.005331082850508196\ \(0\)\
\-\ \\)\\:\\ 0\\.005265960827404465\ \(0\)\
\-\ disease\\:\\ 0\\.00515401306721662\ \(0\)\
\-\ as\\:\\ 0\\.004769658693336265\ \(0\)\
\-\ there\\:\\ 0\\.004692677330129109\ \(0\)\
\-\ a\\:\\ 0\\.0043904037101690175\ \(0\)\
\-\ the\\:\\ 0\\.0040811596960479936\ \(0\)\
\-\ \\.\\:\\ 0\\.0024888973647585948\ \(0\)\
\-\ and\\:\\ 0\\.0019927196206518645\ \(0\)\
\-\ with\\:\\ 0\\.0017269989090758632\ \(0\)\
\-\ of\\:\\ 0\\.0012897099719334513\ \(0\)\
